{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:27Z","timestamp":1788869367785,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["PX2024057"],"award-info":[{"award-number":["PX2024057"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"award":["PX2024057"],"award-info":[{"award-number":["PX2024057"]}],"id":[{"id":"https:\/\/ror.org\/04baakq55","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p &lt; 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p &lt; 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p &lt; 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.<\/jats:p>","DOI":"10.3390\/cancers18182902","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:23:51Z","timestamp":1788866631000},"page":"2902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence Pattern and Prognostic Value of Major Pathological Response in Patients with Locally Advanced Oesophageal Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy: A Multicentre Retrospective Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-0241","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-8905","authenticated-orcid":false,"given":"Xiangyang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Dongjie","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Ran","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang 455000, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"given":"Jianfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shaanxi Provincial People\u2019s Hospital, Xi\u2019an 710068, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Zhentao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Yi","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","article-title":"Epidemiology of Esophageal Squamous Cell Carcinoma","volume":"154","author":"Abnet","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial","volume":"36","author":"Yang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhou, A., Liu, S., He, M., Chen, K., Tian, Z., Li, Y., Qin, J., Wang, Z., and Chen, H. (2023). Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: A randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC. BMC Med., 21.","DOI":"10.1186\/s12916-023-02804-y"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice","volume":"40","author":"Patel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2217\/fon-2020-0189","article-title":"Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Future Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int. J. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109500","DOI":"10.1016\/j.ejso.2024.109500","article-title":"Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy\/chemoimmunotherapy: A multi-center cohort study","volume":"51","author":"Hong","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103792","DOI":"10.1016\/j.breast.2024.103792","article-title":"Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy","volume":"78","author":"Ji","year":"2024","journal-title":"Breast"},{"key":"ref_12","first-page":"100420","article-title":"Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy","volume":"3","author":"Pataer","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12094-023-03342-y","article-title":"Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma","volume":"26","author":"Yan","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Al\u00ec, G., Poma, A.M., Di Stefano, I., Zirafa, C.C., Lenzini, A., Martinelli, G., Romano, G., Chella, A., Baldini, E., and Melfi, F. (2023). Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1115156"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cllc.2019.11.003","article-title":"Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy","volume":"21","author":"Weissferdt","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/dote.12540","article-title":"Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis. Esophagus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/dote.12533","article-title":"Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC\/UICC staging manuals","volume":"29","author":"Rice","year":"2016","journal-title":"Dis. Esophagus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.21037\/jtd.2018.12.07","article-title":"Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma","volume":"11","author":"Mao","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Alsina","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","article-title":"Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer","volume":"34","author":"Liu","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","article-title":"Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cascone","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tian, C., Yu, Y., Wang, Y., Yang, L., Tang, Y., Yu, C., Feng, G., Zheng, D., and Wang, X. (2024). Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: A meta-analysis and systematic review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1352873"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.annonc.2025.12.016","article-title":"Optimizing pathological response assessment after neoadjuvant immunotherapy: Linking clinical practice to drug development","volume":"37","author":"Massi","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2023.03.010","article-title":"Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: Pooled analysis of 29 clinical trials","volume":"186","author":"Nie","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pan.2023.02.005","article-title":"Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma","volume":"23","author":"Bao","year":"2023","journal-title":"Pancreatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtcvs.2018.09.136","article-title":"Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery","volume":"157","author":"Barbetta","year":"2019","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"ezae207","DOI":"10.1093\/ejcts\/ezae207","article-title":"The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy","volume":"65","author":"Zhong","year":"2024","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:48Z","timestamp":1788866928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":32,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182902"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182902","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}